|
Nanobiotix S a (NASDAQ: NBTX) |
|
Nanobiotix S a
NBTX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Nanobiotix S A growth rates, revenue grew
by 658.1 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 92
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Nanobiotix S A net loss decreased from $-64 millions, to $-44 millions in IV. Quarter 2023,
• More on NBTX's Growth
|
|
Nanobiotix S A realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.57 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.94.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.
• More on NBTX's Valuation
|
|
|
|
|
Nanobiotix S A realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 2.57 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.94.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.34.
• More on NBTX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com